StreetInsider.com News Articles

Dermata Therapeutics, Inc (DRMA) Misses Q2 EPS by 19c

Tue, 11 Aug 2026 16:56:57 -0400

Dermata Therapeutics, Inc (NASDAQ: DRMA) reported Q2 EPS of ($0.74), $0.19 worse than the analyst estimate of ($0.55).

For earnings history and earnings-related data on Dermata Therapeutics, Inc (DRMA) click here.

Form 10-Q Dermata Therapeutics, For: Jun 30

Tue, 11 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260811/26905710.html

Form 10-Q Dermata Therapeutics, For: Jun 30

Tue, 11 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260811/26905710.html

Form 8-K Dermata Therapeutics, For: Aug 11

Tue, 11 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260811/26905673.html

Form 8-K Dermata Therapeutics, For: Aug 11

Tue, 11 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260811/26905673.html

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

Tue, 11 Aug 2026 16:05:00 -0400

- Dermata announced the launch date of its first commercial product, Tome™ Foundational Treatment, expected on August 25, 2026 -

- Dermata recently attended Be+Well Beauty and Wellness Show in Las Vegas, NV to announce the Tome brand -

SAN DIEGO, CA / ACCESS Newswire / August 11, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the second quarter ended June 30, 2026.

"Over the past year, we have transformed Dermata through

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

Tue, 11 Aug 2026 16:05:00 -0400

- Dermata announced the launch date of its first commercial product, Tome™ Foundational Treatment, expected on August 25, 2026 -

- Dermata recently attended Be+Well Beauty and Wellness Show in Las Vegas, NV to announce the Tome brand -

"Over the past year, we have transformed Dermata through

Dermata Therapeutics to launch first consumer skincare product Aug. 25

Wed, 05 Aug 2026 08:30:13 -0400

Dermata Therapeutics, Inc. (NASDAQ: DRMA) announced that its Tome Foundational Treatment, the company's first direct-to-consumer skincare product, is planned to launch on August 25, 2026, priced at $178 per set, or approximately $45 per treatment.

The product will be sold exclusively through tomeskincare.com. Consumers who join a waitlist will receive early access to preorder. The set includes four once-weekly treatments, each consisting of a cup of Bioneedle powder, a tube of Activator solution, and a brush for at-home application.

The Tome Foundational Treatment features the company's proprietary Bioneedle technology, which uses a wild-harvested freshwater sponge called Spongilla lacustris. The product is applied

Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment

Wed, 05 Aug 2026 08:30:00 -0400

- A new chapter in skincare has arrived -

- This will be Dermata's first commercial product launch, planned for August 25, 2026 -

- Join the waitlist at tomeskincare.com -

SAN DIEGO, CA / ACCESS Newswire / August 5, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced that Tome Foundational Treatment, the Company's first direct-to-consumer skincare product, is planned to launch on August 25, 2026, with those on the waitlist getting early access to preorder. The launch of the Foundational Treatment

Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment

Wed, 05 Aug 2026 08:30:00 -0400

- A new chapter in skincare has arrived -

- This will be Dermata's first commercial product launch, planned for August 25, 2026 -

- Join the waitlist at tomeskincare.com -

Form 8-K Dermata Therapeutics, For: Aug 05

Wed, 05 Aug 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260805/26870882.html

Form 8-K Dermata Therapeutics, For: Aug 05

Wed, 05 Aug 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260805/26870882.html

Form 4 Dermata Therapeutics, For: Jun 16 Filed by: Scott Kathleen D.

Tue, 16 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260616/26654302.html

Form 4 Dermata Therapeutics, For: Jun 16 Filed by: Scott Kathleen D.

Tue, 16 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260616/26654302.html

Form S-8 Dermata Therapeutics,

Thu, 04 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260604/26605945.html

Form S-8 Dermata Therapeutics,

Thu, 04 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260604/26605945.html

Form SCHEDULE 13D Dermata Therapeutics, Filed by: Van Hoose Kyri K.

Mon, 01 Jun 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260601/26584400.html

Form SCHEDULE 13D Dermata Therapeutics, Filed by: Van Hoose Kyri K.

Mon, 01 Jun 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260601/26584400.html

Form EFFECT Dermata Therapeutics,

Mon, 01 Jun 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260601/26578476.html

Form EFFECT Dermata Therapeutics,

Mon, 01 Jun 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260601/26578476.html

Form 424B3 Dermata Therapeutics,

Fri, 29 May 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260529/26576682.html

Form 424B3 Dermata Therapeutics,

Fri, 29 May 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260529/26576682.html

Form 8-K Dermata Therapeutics, For: May 27

Wed, 27 May 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260527/26558838.html

Form 8-K Dermata Therapeutics, For: May 27

Wed, 27 May 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260527/26558838.html

Dermata Therapeutics, Inc (DRMA) files $100M mixed shelf

Fri, 22 May 2026 17:18:59 -0400

Dermata Therapeutics, Inc (NASDAQ: DRMA) has filed $100,000,000 mixed shelf of:

Common Stock

Preferred Stock

Warrants

Debt Securities

Subscription Rights

Units